These innovative therapies, including Semaglutide , belong to a class of drugs called GLP-1 receptor agonists . Originally developed for controlling diabetes mellitus , they operate by helping the body to release sufficient insulin and limiting excessive sugar levels. Furthermore , their ability to encourage weight loss has resulted to substantial